Identifying endpoints to predict the influence of immunosuppression on long-term kidney graft survival

Clinical Transplantation

Volumn 29, Issue 7, 2015, Pages 644-653

  Srinivas, Titte R ^a   Oppenheimer, Federico ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Acute rejection; Biopsy proven acute rejection; Clinical trial; Endpoint; Glomerular filtration rate; Kidney transplantation; Long term; Renal function

Indexed keywords

CALCINEURIN INHIBITOR; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SOLITARY KIDNEY; DRUG EFFECTS; GRAFT REJECTION; IMMUNOLOGICAL TOLERANCE; KIDNEY FAILURE, CHRONIC;

GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; PROGNOSIS;

EID: 84937143874     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12554     Document Type: Review

References (91)

1. Amico P. Evolution of graft survival in kidney transplantation: an analysis of the OPTN/UNOS Renal Transplant Registry. Clin Transpl 2010: 1.
2. Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 2011: 11: 450.
3. Marcén R, Fernández-Rodriguez A, Rodríguez-Mendiola N et al. Evolution of rejection rates and kidney graft survival: a historical analysis. Transplant Proc 2009: 41: 2357.
4. Matas AJ, Smith JM, Skeans MA et al. OPTN/SRTR 2011 Annual Data Report: kidney. Am J Transplant 2013: 13(Suppl 1): 11.
5. Schold JD, Kaplan B. The elephant in the room: failings of current clinical endpoints in kidney transplantation. Am J Transplant 2010: 10: 1163.
6. U.S. Food and Drug Administration. Endpoints for Clinical Trials in Kidney Transplantation; Public Workshop. http://www.fda.gov/Drugs/NewsEvents/ucm305308.htm Accessed 1 December 2014.
7. European Medicines Agency. Guideline on clinical investigation of immunosuppressants for solid organ transplantation. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003593.pdf (Accessed 1 December 2014).
8. Molner MZ, Streja E, Kovesdy CP et al. Age and the associations of living donor and expanded criteria donor kidneys with kidney transplant outcomes. Am J Kidney Dis 2012: 59: 841.
9. Gore JL, Pham PT, Danovitch GM et al. Obesity and outcome following renal transplantation. Am J Transplant 2006: 6: 357.
10. Øien CM, Reisaeter AV, Leivestad T, Dekker FW, Line PD, Os I. Living donor kidney transplantation: the effects of donor age and gender on short- and long-term outcomes. Transplantation 2007: 83: 600.
11. Dunn TB, Noreen H, Gillingham K et al. Revisiting traditional risk factors for rejection and graft loss after kidney transplantation. Am J Transplant 2011: 11: 2132.
12. Kuo HT, Sampaio MS, Vincenti F, Bunnapradist S. Associations of pretransplant diabetes mellitus, new-onset diabetes after transplant, and acute rejection with transplant outcomes: an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing (OPTN/UNOS) database. Am J Kidney Dis 2010: 56: 1127.
13. Cole EH, Johnston O, Rose CL, Gill JS. Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival. Clin J Am Soc Nephrol 2008: 3: 814.
14. Coupel S, Giral-Classe M, Karam G et al. Ten-year survival of second kidney transplants: impact of immunologic factors and renal function at 12 months. Kidney Int 2003: 64: 674.
15. Hariharan S, McBride M, Cherikh W et al. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002: 62: 311.
16. Kasiske BL, Israni AK, Snyder JJ et al. The relationship between kidney function and long-term graft survival after kidney transplant. Am J Kidney Dis 2011: 57: 466.
17. Lenihan CR, O'Kelly P, Mohan P et al. MDRD-estimated GFR at one year post-renal transplant is a predictor of long-term graft function. Ren Fail 2008: 30: 345.
18. Wu J, Li H, Huang H et al. Slope of changes in renal function in the first year post-transplantation and one-yr estimated glomerular filtration rate together predict long-term renal allograft survival. Clin Transplant 2010: 24: 862.
19. Jindal RM, Das NP, Neff RT et al. Outcomes in African-Americans vs. Caucasians using thymoglobulin or interleukin-2 receptor inhibitor induction: analysis of USRDS database. Am J Nephrol 2009: 29: 501.
20. Naesens M, Kuypers DR, De Vusser K et al. Chronic histological damage in early indication biopsies is an independent risk factor for late renal allograft failure. Am J Transplant 2013: 13: 86.
21. Moreso F, Ibernon M, Gomà M et al. Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss. Am J Transplant 2006: 6: 747.
22. Mannon RB, Matas AJ, Grande J et al. Inflammation in areas of tubular atrophy in kidney allograft biopsies: a potent predictor of allograft failure. Am J Transplant 2010: 10: 2066.
23. Park WD, Griffin MD, Cornell LD, Cosio FG, Stegall MD. Fibrosis with inflammation at one year predicts transplant functional decline. J Am Soc Nephrol 2010: 21: 1987.
24. De Fijter J, Mallat MJ, Doxiadis II et al. Increased immunogenicity and cause of graft loss of old donor kidneys. J Am Soc Nephrol 2001: 12: 1538.
25. Tullius SG, Tran H, Guleria I, Malek SK, Tilney NL, Milford E. The combination of donor and recipient age is critical in determining host immunoresponsiveness and renal transplant outcome. Ann Surg 2010: 252: 662.
26. Aoun B, Decramer S, Vitkevic R et al. Protocol biopsies in pediatric renal transplant recipients on cyclosporine versus tacrolimus-based immunosuppression. Pediatr Nephrol 2013: 28: 493.
27. Roberts IS, Stratopoulos C, Zilvetti M, Reddy S, Friend PJ. Impact of immunosuppression on the incidence of early subclinical renal allograft rejection: implications for protocol biopsy policy. Transpl Int 2009: 22: 831.
28. Murakami N, Riella LV, Funakoshi T. Risk of metabolic complications in kidney transplantation after conversion to mTOR inhibitor: a systematic review and meta-analysis. Am J Transplant 2014: 14: 2317.
29. United States Renal Data System (USRDS) Annual Report 2012. Available at http://www.usrds.org/adr.aspx.
30. Saidi RF, Elias N, Kawai T et al. Outcome of kidney transplantation using expanded criteria donors and donation after cardiac death kidneys: realities and costs. Am J Transplant 2007: 12: 2769.
31. Mao Q, Terasaki PI, Cai J et al. Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study. Am J Transplant 2007: 7: 864.
32. Hourmant M, Cesbron-Gautier A, Terasaki PI et al. Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation. J Am Soc Nephrol 2005: 16: 2804.
33. Gatault P, Halimi JM, Forconi C et al. CMV infection in the donor and increased kidney graft loss: impact of full HLA-I mismatch and posttransplantation CD8(+) cell reduction. Am J Transplant 2013: 13: 2119.
34. Morales JM, Marcén R, Andres A et al. Renal transplantation in patients with hepatitis C antibody. A long national experience. NDT Plus 2010: 3(Suppl 2): ii41.
35. Singh N, Neidlinger N, Djamali A et al. The impact of hepatitis C virus donor and recipient status on long-term kidney transplant outcomes: University of Wisconsin experience. Clin Transplant 2012: 26: 684.
36. Opelz G, Döhler B; Collaborative Transplant Study. Improved long-term outcomes after renal transplantation associated with blood pressure control. Am J Transplant 2005: 5: 2725.
37. Mange KC, Cizman B, Joffe M, Feldman HI. Arterial hypertension and renal allograft survival. JAMA 2000: 283: 633.
38. Kasiske BL, Anjum S, Shah R et al. Hypertension after kidney transplantation. Am J Kidney Dis 2004: 43: 1071.
39. Stock PG, Barin B, Murphy B et al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med 2010: 363: 2004.
40. Jones H, Talwar M, Nogueira JM et al. Anemia after kidney transplantation; its prevalence, risk factors, and independent association with graft and patient survival: a time-varying analysis. Transplantation 2012: 93: 923.
41. de Andrade LG, Abrão JM, Carvalho MF. I Anemia at one year is an independent risk factor of graft survival. Int Urol Nephrol 2012: 44: 263.
42. Schjelderup P, Dahle DO, Holdaas H et al. Anemia is a predictor of graft loss but not cardiovascular events and all-cause mortality in renal transplant recipients: follow-up data from the ALERT study. Clin Transplant 2013: 27: E636.
43. Taber DJ, Meadows HB, Pilch NA, Chavin KD, Baliga PK, Egede LE. Pre-existing diabetes significantly increases the risk of graft failure and mortality following renal transplantation. Clin Transplant 2013: 27: 274.
44. Suwelack B, Malyar V, Koch M, Sester M, Sommerer C. The influence of immunosuppressive agents on BK virus risk following kidney transplantation, and implications for choice of regimen. Transplant Rev (Orlando) 2012: 26: 201.
45. Acott P, Babel N. BK virus replication following kidney transplant: does the choice of immunosuppressive regimen influence outcomes? Ann Transplant 2012: 17: 86.
46. Mohan S, Palanisamy A, Tsapepas D et al. Donor-specific antibodies adversely affect kidney allograft outcomes. J Am Soc Nephrol 2012: 23: 2061.
47. Lefaucheur C, Loupy A, Hill GS et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010: 21: 1398.
48. Prendergast MB, Gaston RS. Optimizing medication adherence: an ongoing opportunity to improve outcomes after kidney transplantation. Clin J Am Soc Nephrol 2010: 5: 1305.
49. Sellarés J, de Freitas DG, Mengel M et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012: 12: 388.
50. Nevins TE, Robiner WN, Thomas W. Predictive patterns of early medication adherence in renal transplantation. Transplantation 2014: 98: 878.
51. Griva K, Davenport A, Harrison M, Newman SP. Non-adherence to immunosuppressive medications in kidney transplantation: intent vs. forgetfulness and clinical markers of medication intake. Ann Behav Med 2012: 44: 85.
52. Dharancy S, Giral M, Tetaz R, Fatras M, Dubel L, Pageaux GP. Adherence with immunosuppressive treatment after transplantation: results from the French trial PREDICT. Clin Transplant 2012: 26: E293.
53. Opelz G, Döhler B. Effect of human leukocyte antigen compatibility on kidney graft survival: comparative analysis of two decades. Transplantation 2007: 84: 137.
54. Yarlagadda SG, Coca SG, Formica RN Jr, Poggio ED, Parikh CR. Association between delayed graft function and allograft and patient survival: a systematic review and meta-analysis. Nephrol Dial Transplant 2009: 24: 1039.
55. Quiroga I, McShane P, Koo DD et al. Major effects of delayed graft function and cold ischaemia time on renal allograft survival. Nephrol Dial Transplant 2006: 21: 1689.
56. Mikhalski D, Wissing KM, Ghisdal L et al. Cold ischemia is a major determinant of acute rejection and renal graft survival in the modern era of immunosuppression. Transplantation 2008: 85(7 Suppl): S3.
57. Lebranchu Y, Baan C, Biancone L et al. Pretransplant identification of acute rejection risk following kidney transplantation. Transpl Int 2014: 27: 129.
58. Vincenti F, Friman S, Scheuermann E et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007: 7: 1506.
59. Roland M, Gatault P, Doute C et al. Immunosuppressive medications, clinical and metabolic parameters in new-onset diabetes mellitus after kidney transplantation. Transpl Int 2008: 21: 523.
60. Ducloux D, Motte G, Kribs M et al. Hypertension in renal transplantation: donor and recipient risk factors. Clin Nephrol 2002: 57: 409.
61. Srinivas TR, Flechner SM, Poggio ED et al. Glomerular filtration rate slopes have significantly improved among renal transplants in the United States. Transplantation 2010: 90: 1499.
62. Sijpkins YW, Doxiadis II, Mallat MJ et al. Early versus late acute rejection episodes in renal transplantation. Transplantation 2003: 75: 204.
63. Joseph JT, Kingsmore DB, Junor BJ et al. The impact of late acute rejection after cadaveric kidney transplantation. Clin Transplant 2001: 15: 221.
64. Lentine KL, Gheorghian A, Axelrod D, Kalsekar A, L'italien G, Schnitzler MA. The implications of acute rejection for allograft survival in contemporary U.S. kidney transplantation. Transplantation 2012: 94: 639.
65. McDonald S, Russ G, Campbell S, Chadban S. Kidney transplant rejection in Australia and New Zealand: Relationships between rejection and graft outcome. Am J Transplant 2007: 7: 1201.
66. Rodrigues CA, Franco MF, Cristelli MP, Pestana JO, Tedesco-Silva H Jr. Clinicopathological characteristics and effect of late acute rejection on renal transplant outcomes. Transplantation 2014: 98: 885.
67. Belitsky P, MacDonald AS, Lawen J et al. Kidney transplantation, the Halifax experience. Clin Transplant 1996: 231.
68. Dörje C, Midtvedt K, Holdaas H et al. Early versus late acute antibody-mediated rejection in renal transplant recipients. Transplantation 2013: 96: 79.
69. Meier-Kreische H-U, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004: 4: 378.
70. Salvadori M, Rosati A, Bock A et al. One-year posttransplant renal function is a strong predictor of long-term kidney function: results from the Neoral-MOST Observational Study. Transplant Proc 2003: 35: 2863.
71. He X, Moore J, Shabir S et al. Comparison of the predictive performance of eGFR formulae for mortality and graft failure in renal transplant recipients. Transplantation 2009: 87: 384.
72. Thompson A, Lawrence J, Stockbridge N. GFR decline as an end point in trials of CKD: a viewpoint from the FDA. Am J Kidney Dis 2014: 64: 836.
73. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 2002: 39 (2 Suppl 2): S1.
74. Pascual J, Srinivas TR, Chadban S et al. TRANSFORM: a novel study design to evaluate the effect of everolimus on long-term outcomes after kidney transplantation. Open Access J Clin Trials 2014: 6: 45.
75. Ekberg H, Tedesco-Silva H, Demirbas A et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007: 357: 2562.
76. Budde K, Becker T, Arns W et al. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 2011: 377: 837.
77. Durrbach A, Pestana JM, Pearson T et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010: 10: 547.
78. Vincenti F, Charpentier B, Vanrenterghem Y et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010: 10: 535.
79. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004: 78: 557.
80. Issa N, Kukla A, Ibrahim HN. Calcineurin inhibitor nephrotoxicity: a review and perspective of the evidence. Am J Nephrol 2013: 37: 602.
81. Chapman JR. Chronic calcineurin inhibitor nephrotoxicity-lest we forget. Am J Transplant 2011: 11: 693.
82. Nankivell BJ, Kuypers DR. Diagnosis and prevention of chronic kidney allograft loss. Lancet 2011: 378: 1428.
83. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. Natural history, risk factors, and impact of subclinical rejection in kidney transplantation. Transplantation 2004: 78: 242.
84. Moreso F, Carrera M, Goma M et al. Early subclinical rejection as a risk factor for late chronic humoral rejection. Transplantation 2012: 93: 41.
85. Roberts IS, Reddy S, Russell C et al. Subclinical rejection and borderline changes in early protocol biopsy specimens after renal transplantation. Transplantation 2004: 77: 1194.
86. Marcén R, Morales JM, Fernández-Rodriguez A et al. Long-term graft function changes in kidney transplant recipients. NDT Plus 2010: 2(Suppl_2): ii2.
87. Stoycheff N, Pandya K, Okparavero A et al. Early change in proteinuria as a surrogate outcome in kidney disease progression: a systematic review of previous analyses and creation of a patient-level pooled dataset. Nephrol Dial Transplant 2011: 26: 848.
88. Chang TI, Li S, Chen SC et al. KEEP Investigators. Risk factors for ESRD in individuals with preserved estimated GFR with and without albuminuria: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2013: 61: S4.
89. Brokhof MM, Sollinger HW, Hager DR et al. Antithymocyte globulin is associated with a lower incidence of de novo donor-specific antibodies in moderately sensitized renal transplant recipients. Transplantation 2014: 97: 612.
90. Lionaki S, Panagiotellis K, Iniotaki A, Boletis JN. Incidence and clinical significance of de novo donor specific antibodies after kidney transplantation. Clin Dev Immunol 2013: 2013: 849835.
91. Fernández-Fresnedo G, Palomar R, Escallada R et al. Hypertension and long-term renal allograft survival: effect of early glomerular filtration rate. Nephrol Dial Transplant 2001: 16(Suppl 1): 105.